Exploring the balance between efficacy and safety in advanced lung cancer treatment, focusing on the risk of drug-induced interstitial lung disease from targeted therapies like osimertinib and savolitinib.
Exploring the molecular mechanisms linking lung cancer and tuberculosis, their shared immune pathways, and implications for treatment.